Submit a Comment

LATITUDE Changes Attitude Toward Metastatic Prostate Cancer

  1. Fizazi K, et al. “Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer;” N Eng J Med. 2017 June 4 [epub ahead of print].
  2. Kantar Health, CancerMPact® Treatment Architecture U.S., accessed June 4, 2017.
  3. Janssen Japan Press Release; “Zytiga® for prostate cancer treatment "hormone therapy" Application for adaptation of untreated metastatic prostate cancer;” accessed June 4, 2017 < http://www.janssen.com/japan/press-release/20170526>.
  4. Efstathiou E, et al.; “Cytoreduction and androgen signaling modulation by abiraterone acetate plus leuprolide acetate (LHRHa) vs LHRHa in localized high risk prostate cancer: preliminary results of a randomized preoperative study,” J Clin Oncol 30, 2012 (suppl; abstr 4556).
  5. Fizazi K, et al. “LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer;” J Clin Oncol 35, 2017 (suppl; abstr LBA3).
  6. James N, et al. “Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476);” J Clin Oncol 35, 2017 (suppl; abstr LBA5003).
  7. Sweeney C, et al. “Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial;” Ann Oncol (2016) 27 (suppl_6): 720PD.
 

Post a Comment

Your email is never shared. Required fields are marked *